Drug screens and CRISPR combine to help make better cancer drugs

Drug screens and CRISPR combine to help make better cancer drugs
A new study has created the most comprehensive analysis for understanding how cancer drugs work at a molecular level. Scientists at the Wellcome Sanger Institute, EMBL's European Bioinformatics Institute (EMBL-EBI) and AstraZeneca combined drug response data with CRISPR genetic screens across hundreds of cancer cell lines to better understand precisely how drugs target cancer cells.